Following is a cumulative list of Hoosier Cancer Research Network publications in gynecologic cancers.

Manuscripts and Journal Articles

• R. Ramasubbaiah, S.M. Perkins, J. Schilder, C. Whalen, C.S. Johnson, M. Callahan, T. Jones, G. Sutton, D. Matei. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group: GYN06-111. Gynecologic Oncology (2011). DOI:10.1016/j.ygyno.2011.08.033. PMID: 21955480
• Daniela Matei, Jeanne Schilder, Gregory Sutton, Susan Perkins, Tim Breen, Check Quon, Carolyn Sidor. Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial GYN06-106, Gynecologic Oncology 115 (2009) 90–96. PMID: 19577796
• Matei D, Emerson RE, Schilder J, Menning N, Baldridge LA, Johnson CS, Breen T, McClean J, Stephens D, Whalen C, Sutton G. Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis, a Hoosier Oncology Group Trial GYN03-62. CANCER, 2008 Aug 15;113(4):723-32. PMID: 18618737
• Achilles J. Fakiris, Higinia R. Cardenes, David H. Moore, Shailaja R. Reddy, Katherine Y. Look, Constantin T. Yiannoutsos, Marcus E. Randall. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Hoosier Oncology Group Study GYN97-1. Gynecologic Oncology, 2005; 96: 818-823
• Shaheen M1, Stender MJ, McClean JW, Look KY, Einhorn LH. Phase II study of ifosfamide plus daily oral etoposide in previously treated ovarian cancer: a Hoosier Oncology Group (HOG) study. GYN98-1. Am J Clin Oncol. 2004 Jun;27(3):229-31. PMID: 15170139

Abstracts, Posters, and Presentations

• M.C. deLeon, A. Arnold, E.C. Rossi, J. Case, C. Johnson, Y. Zeng, D. Matei. Phase I trial of pegylated liposomal doxorubicin in combination with BIBF 1120 (nintedanib) in platinum-resistant ovarian cancer: Hoosier Oncology Group GYN10-149. Accepted to the gynecologic cancer general poster session at the ASCO Annual Meeting May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr 5541^)
• D. Matei, R. Ramasubbaiah, J. Schilder, S. M. Perkins, C. Whalen, T. Breen, C. S. Johnson, M. Callahan, T. Jones, G. Sutton. A phase I/II study of topotecan and sorafenib in recurrent, platinum-resistant ovarian cancer: Hoosier Oncology Group GYN06-111. Accepted to the scientific program in the general poster session at the ASCO Annual Meeting June 4-8, 2010, Chicago, IL. J Clin Oncol 28:15s, 2010 (suppl; abstr 5108)
• D. Matei, J. Schilder, N. Menning, K. Koneru, G. Sutton. A Phase II, Open-Label, Safety and Efficacy Study of Panzem Nanocrystal Colloidal Dispersion Administered Orally in Patients with Recurrent or Resistant Epithelial Ovarian Cancer: Hoosier Oncology Group GYN06-106. Accepted for poster presentation at the 2007 AACR (American Association for Cancer Research) -NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA
• Daniela Matei, Robert E. Emerson, Nancy Menning, Jeanne Schilder, John McClean, Greg Sutton, Doyle Stephens, Misty Witherite, Charles Whalen, David H. Moore. Clinical Activity of Imatinib Mesylate (Gleevec) In Combination with Docetaxel In Patients With Advanced, Platinum-Resistant Ovarian Cancer Or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62. Accepted to the ASCO Annual Meeting June 2-6, 2006, Atlanta, GA
• Achilles J. Fakiris, Higinia R. Cardenes, David H. Moore, Shailaja R. Reddy, Katherine Y. Look, Constantin T. Yiannoutsos, Marcus E. Randall. Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Hoosier Oncology Group GYN97-1 study. Accepted at the Society of Gynecologic Oncologists Annual Meeting February 7-11, 2004, San Diego, CA. Gynec Oncol, 92(2004); 439.
• Montaser Shaheen, John W. McClean, Lawrence H. Einhorn. A Phase II Study of Ifosfamide plus Etoposide in Previously treated Ovarian Cancer, A Hoosier Oncology Group Study GYN98-1. Accepted to the ASCO Annual Meeting May 12-15, 2001, San Francisco, CA